Corvus Pharmaceuticals (CRVS) Receivables (2022 - 2026)
Corvus Pharmaceuticals (CRVS) recorded quarterly Receivables of $43000.0 in Q1 2026, up 16.22% quarter-over-quarter from $37000.0 in Q4 2025, and down 45.57% on a YoY basis from $79000.0 in Q1 2025.
Corvus Pharmaceuticals (CRVS) Receivables (2022 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Receivables history runs 5 years deep, the most recent figure standing at $43000.0 for Q1 2026.
- In Q1 2026, Receivables fell 45.57% year-over-year to $43000.0; the TTM figure through Mar 2026 stood at $43000.0 (down 45.57% YoY), while the FY2025 annual figure was $37000.0, down 50.67% from the prior year.
- Receivables was $43000.0 for Q1 2026 at Corvus Pharmaceuticals, up from $37000.0 in the prior quarter.
- In the past five years, Receivables ranged from a high of $1.2 million in Q4 2022 to a low of $11000.0 in Q3 2023.
- Historically, Receivables has averaged $154416.7 across 5 years, with a median of $61000.0 in 2023.
- The sharpest annual moves came in 2023 and 2024: Receivables slumped 95.58% in 2023, then jumped 1172.73% in 2024.
- A 5-year view of Receivables shows it stood at $1.2 million in 2022, then plunged by 95.58% to $52000.0 in 2023, then jumped by 44.23% to $75000.0 in 2024, then slumped by 50.67% to $37000.0 in 2025, then rose by 16.22% to $43000.0 in 2026.
- The last three Receivables figures came in at $43000.0 (Q1 2026), $37000.0 (Q4 2025), and $32000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 13.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 2.00 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Corvus Pharmaceuticals | 1.00 Bn | 766.75 Mn | - | 43,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 43,000.00 |
| Dec 31, 2025 | 37,000.00 |
| Sep 30, 2025 | 32,000.00 |
| Jun 30, 2025 | 86,000.00 |
| Mar 31, 2025 | 79,000.00 |
| Dec 31, 2024 | 75,000.00 |
| Sep 30, 2024 | 140,000.00 |
| Jun 30, 2024 | 70,000.00 |
| Mar 31, 2024 | 52,000.00 |
| Dec 31, 2023 | 52,000.00 |
| Sep 30, 2023 | 11,000.00 |
| Dec 31, 2022 | 1.18 Mn |